Does apixaban improve safety outcomes (bleeding rates) compared to warfarin in patients with end-stage renal disease?
Apixaban showed similar bleeding rates to warfarin in end-stage renal disease patients, suggesting it may be a cautious alternative.
There were no observed differences in bleeding rates in patients receiving apixaban compared with those receiving warfarin. Apixaban may be a cautious consideration in hemodialysis patients until there is further insight into the effect of subsequent, multiple doses on drug accumulation and clinical outcomes.
Sarratt et al. (2017) studied this question.